Salveen Richter

“Perhaps just in the context of the confounding factors here, the translational aspect, the PK exposure, the DDIs, Walk us through the scenarios for the FORD here, like what you're, you know, in the context of, you know, what you could learn.”

“One is, could you provide more details on the survey arbitration given the ruling that you have to engage in discussions with ALO regarding the direct licensing of 501 and help us understand how this impacts your eligibility for the $340 million in milestones into this interim data?”

“It's my pleasure to introduce the Amgen team. With us, we have Peter Griffiths, Chief Financial Officer, Murdo Gordon, Head of Global Commercial Operations, Andrew Martin, Head of U.S. Business Operations, and Casey Caporelli, Head of Investor Relations.”

“Can you remind us of the background stabilizer used in the study and if you expect that to change given recent cardio transform results? Also on the HLA finding, do you see enrollment changes just given screening for HLA?”

“One is you announced that the phase 2-3 Olympus study for POV in PMN is going to move to phase 3 with an 80 milligram dose every four weeks. Can you frame what signal this was based on and whether you are the DSMB or what you or the DSMB saw in the Phase 2B portion to move forward.”